FFA
AXSM icon

Farther Finance Advisors’s Axsome Therapeutics AXSM Stock Holding History

Farther Finance Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$69K Sell
374
-141
-27% -$30.7K ﹤0.01% 3154
2026
Q2 		$126K Buy
515
+223
+76% +$48.4K ﹤0.01% 2546
2026
Q1 		$50.2K Buy
292
+18
+7% +$3.11K ﹤0.01% 2995
2025
Q4 		$50K Buy
274
+235
+603% +$32.8K ﹤0.01% 2816
2025
Q3 		$4.74K Buy
39
+10
+34% +$1.13K ﹤0.01% 3789
2025
Q2 		$3.03K Sell
29
-10
-26% -$1.06K ﹤0.01% 3552
2025
Q1 		$4.36K Sell
39
-3
-7% -$342 ﹤0.01% 3118
2024
Q4 		$3.55K Hold
42
– – ﹤0.01% 2803
2024
Q3 		$3.77K Hold
42
– – ﹤0.01% 2764
2024
Q2 		$3.4K Buy
42
+32
+320% +$2.37K ﹤0.01% 2566
2024
Q1 		$770 Sell
10
-1
-9% -$84 ﹤0.01% 2872
2023
Q4 		$875 Buy
+11
New +$735 ﹤0.01% 2787

Other funds holding AXSM

MCP
Mirador Capital Partners Pleasanton, California $859M AUM 41.74% 1-Year Est. Return
AAG
Armstrong Advisory Group Needham, Massachusetts $1.66B AUM 13.15% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
MAM
Marquette Asset Management Minneapolis, Minnesota $766M AUM 16.04% 1-Year Est. Return

Farther Finance Advisors's AXSM Position: Q3 2026 in Review

Farther Finance Advisors reduced its Axsome Therapeutics (AXSM) stake by 27% in Q3 2026, selling an estimated $30.7K and leaving 374 shares worth $69K. The position accounts for ﹤0.01% of the portfolio, ranked #3154.

Farther Finance Advisors first reported a position in AXSM in Q4 2023 and has held it in 12 quarters since. The position peaked at $126K in Q2 2026. 7 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.

  • Farther Finance Advisors held 374 shares of Axsome Therapeutics worth $69K as of Q3 2026.
  • Farther Finance Advisors sold 141 Axsome Therapeutics shares in Q3 2026, an estimated $30.7K.
  • Axsome Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #3154 holding.
  • Farther Finance Advisors first reported a position in Axsome Therapeutics in Q4 2023 and has held it in 12 quarters since.
  • Farther Finance Advisors's Axsome Therapeutics position peaked at $126K in Q2 2026.
  • 7 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.

Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.